Asset Details
Do you wish to reserve the book?
Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors
Do you wish to request the book?
Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors
2021
Overview
Coronavirus disease 2019 (COVID‐19) is associated with high rates of thromboembolic events in hospitalized patients. It remains to be determined if this risk persists following hospital discharge.
We conducted a retrospective cohort study of outpatients recently hospitalized for COVID‐19 to determine the incidence of vascular thromboembolic events within 30 days of discharge. We investigated the risk factors associated with these events, including intensive care admission, age, and anticoagulation.
Among 447 patients hospitalized for COVID‐19, 2.0% experienced a vascular thromboembolic event within 30 days of discharge. No risk factor variable was significantly associated with an increased risk for these events.
The incidence of vascular thromboembolic events following hospital discharge for COVID‐19 is low. These findings suggest against the routine use of postdischarge thromboprophylaxis in patients with COVID‐19.
Publisher
Elsevier Inc,Elsevier Limited,John Wiley and Sons Inc,Elsevier
Subject
